Recruiting

Vasopressin

Sponsor:

Prisma Health-Upstate

Code:

NCT07102615

Conditions

Retained Products of Conception

Eligibility Criteria

Sex: Female

Age: 18 - 51

Healthy Volunteers: Not accepted

Interventions

Intracervical injection of Vasopressin

Intracervical Injection of saline

Study Details

Brief summary:

This randomized study looks at whether using a medicine injected into the cervix of the uterus (intracervical), called vasopressin, helps to achieve better removal of retained products of conception (RPOC). RPOC means that after a pregnancy has ended (through miscarriage, abortion, or delivery), some parts of the pregnancy tissue, usually from the placenta or fetus, have stayed in the uterus. A hysteroscopic removal of RPOC is one type of treatment. This is a surgical procedure where a doctor uses a small camera attached to a thin tube (called a hysteroscope) to look inside the uterus.

The main goal of the study is :

• To add to the existing research through this study to see if the injection of intracervical vasopressin leads to improved completion rates of hysteroscopic management of RPOC.

Participants will:

• would be randomized to receive either vasopressin intracervical injection or a placebo injection (non-active saline) during your procedure. Information from the procedure will be collected from the participant's medical record.

Conditions

Retained Products of Conception

Study ID

NCT07102615

Start date

Oct 30, 2025

Status verified date

Oct, 2025

Completion date

Dec 1, 2026

Anticipated

Primary completion date

Aug 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 51

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Women
  • Aged 18-51
  • Undergoing surgical management for retained products of conception, postpartum retained products of conception or 1st trimester missed or incomplete abortion

Exclusion Criteria:

  • Hemodynamic instability
  • Active hemorrhage- soaking pad/hour
  • Allergy to vasopressin
  • Concern for intrauterine arteriovenous malformation
  • Inability to consent

Study Design

Enrollment

50 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Treatment

Vasopressin- 20 mL of a dilute solution (5 units of Vasopressin in 20cc injectable saline)

placebo comparator: Placebo

20 mL of saline

Interventions

Intracervical injection of Vasopressin

Intracervical injection of Vasopressin

Intracervical Injection of saline

Intracervical Injection of saline

Primary outcome measure

  • Completion of procedure hysteroscopically [ Time Frame: from start of procedure to end of procedure ]

Central Contacts and Locations

Locations

The OB/GYN Center

Recruiting

Greenville, South Carolina, United States, 29605

Contacts

More Information

Sponsor

Prisma Health-Upstate

Last update posted

Nov 4, 2025

Last verified

Oct, 2025

Keywords

  • retained products of conception
  • intracervical
  • hysteroscopy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Prisma Health-Upstate on 2025-11-04.